Find out what’s in the drug pipeline for autoimmune disease.
Drug Class Overview
Early planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars.
FDA’s approval of the first generic version of Copaxone for treating patients with relapsing forms of multiple sclerosis has industry insiders contemplating the impact on the generics market as well as payer coverage strategies.
Increasing unnecessary regulations on drug plans could inflict higher costs on the 220 million Americans who get their medications through a managed drug plan, according to a new report.
Controversy surrounds the 340B Drug Discount Program, and many industry leaders agree that the healthcare law plays a large part.
Drug shortages and manufacturer consolidation are leaving their imprint on the price of some generic drugs.
19 out of 20 patients who think they are allergic to penicillin are wrong and are costing 63% more
Drug shortages remain a serious problem for patient safety, according to newly published results from a survey of pharmacy directors.
Breakthrough Therapy Designation given to daclatasvir and asunaprevir